Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement

(2013)   ANNALS OF INTERNAL MEDICINE

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

(2012) Eugene V McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA)

(2011) E. Landfeldt et al.   OSTEOPOROSIS INTERNATIONAL

Interpretation and use of FRAX in clinical practice

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women

(2011) Graham Scotland et al.   PHARMACOECONOMICS

FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

(2010) O. Ström et al.   BONE

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

(2010) B. Jönsson et al.   OSTEOPOROSIS INTERNATIONAL

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women

(2010) John A. Kanis et al.   Archives of Osteoporosis

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years

(2009) J.Y. Reginster et al.   BONE

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

(2009) J. Compston et al.   MATURITAS

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

(2009) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

(2009) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

(2008) Ström Oskar et al.   Acta Orthopaedica

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)

(2008) S. Fujiwara et al.   OSTEOPOROSIS INTERNATIONAL

Incorporating adherence into health economic modelling of osteoporosis

(2008) O. Ström et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

The cost-effectiveness of alendronate in the management of osteoporosis

(2007) John A. Kanis et al.   BONE

Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis

(2006) Carolyn M. Klotzbuecher et al.   JOURNAL OF BONE AND MINERAL RESEARCH